DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today announced that its Board of Directors has authorized an increase by $50 million to $100 million in the Company’s share repurchase prog…
Category: Business
Kubota Vision Announces Publication in Scientific Reports of Study Data for Wearable Myopia-Control Device
SEATTLE–(BUSINESS WIRE)–Kubota Vision Inc. (Kubota Vision), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of a new paper in the j…
Global Graves' Ophthalmopathy Clinical Trials Market Research Report, H2 2021 Review – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Graves’ Ophthalmopathy – Global Clinical Trials Review, H2, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This clinical trial report provides an overview of the Graves’ Ophthalmopathy Clinical …
VARIANT Receives European Orphan Drug Designation for its Gene Therapy Product Candidate, VAR002, for the Treatment of Both Leber Congenital Amaurosis and Cone-Rod dystrophy
PARIS–(BUSINESS WIRE)–VARIANT Receives European Orphan Drug Designation for its Gene Therapy Product Candidate, VAR002, for the Treatment of Both LCA and CORD.
ProtoKinetix Announces Selection of AAGP® Candidate Formulations for Treatment of Dry Eye Disease
MARIETTA, Ohio–(BUSINESS WIRE)–ProtoKinetix Announces Selection of AAGP® Candidate Formulations for Treatment of Dry Eye Disease
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Amneal Receives Approval for Difluprednate Ophthalmic Emulsion
BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for diflupr…
Clinical Ink est classée parmi les société à la croissance la plus rapide d’Amérique du Nord dans le palmarès Technology Fast 500™ 2021 de Deloitte
HORSHAM, Pennsylvanie–(BUSINESS WIRE)–Clinical Ink a annoncé aujourd’hui qu’elle avait été classée dans le palmarès Technology Fast 500™, un classement des 500 sociétés connaissant la plus forte croissance dans les secteurs de la technologie, des méd…
Riassunto: Clinical Ink annoverata tra le aziende nordamericane in più rapida crescita nella classifica Deloitte Fast 500™ del 2021
HORSHAM, Pennsylvania–(BUSINESS WIRE)–Clinical Ink ha annunciato oggi di essere stata inclusa nella 27a edizione di Deloitte Technology Fast 500™, una classifica delle 500 aziende nordamericane in più rapida crescita operanti nei settori tecnologico,…
Clinical Ink Ranked Among Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500™
HORSHAM, Pa.–(BUSINESS WIRE)–Clinical Ink today announced it ranked on the Deloitte Technology Fast 500™, growing 293% during this period.
National Vision Announces 2021-2022 Scholarship Program, Focusing on Importance of Accessible Eye Care
DULUTH, Ga.–(BUSINESS WIRE)– #eyecare–National Vision, Inc., the nation’s second largest optical retailer providing quality, affordable eye care and eyewear, announced today that its annual scholarship program is open for entries, giving eligible op…
Eye Associates Northwest Enters Partnership with Comprehensive EyeCare Partners
LAS VEGAS & SEATTLE–(BUSINESS WIRE)– #COMPEYE–CompEye, one of the largest vision care practice management organizations in the nation, announces a partnership with Eye Associates Northwest.
Kedalion Therapeutics Secures Series B Funding and Announces Signing of Option to Acquire Agreement
MENLO PARK, Calif.–(BUSINESS WIRE)–Kedalion Therapeutics has announced completion of its Series B financing led by Novartis and involving a combination of new and existing investors.
jCyte Identifies Key Anatomical Biomarker Predictive of Substantial Restoration of Visual Function in Retinitis Pigmentosa Patients Treated With jCell Therapy
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte, Inc., today announced key findings presented at AAO 2021 which demonstrated that retinitis pigmentosa (RP) patients with a baseline central visual field diameter greater than 20 degrees had a profound resp…
Worldwide Novel Ocular Drug Delivery Devices Industry to 2030 – Featuring Aciont, AcuFocus and Allergan Among Others – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Novel Ocular Drug Delivery Devices Market: Focus on Implants, Inserts and Punctal Plugs – Distribution by Type of Drug Delivery Device, Target Indications, Type of Product and Key Geographies: Industry Trends and Global Fo…
Horizon Therapeutics plc recibe la opinión positiva del CHMP para UPLIZNA® (inebilizumab) como monoterapia para el tratamiento de pacientes adultos con trastorno del espectro de la neuromielitis óptica (NMOSD)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) ha anunciado hoy que el Comité de Medicamentos de Uso Humano (CHMP) de la Agencia Europea de Medicamentos (EMA) ha adoptado una opinión positiva recomendando la autorización de comerciali…
ModMed® Surpasses 100 Million Patient Encounters in Eye Care
NEW ORLEANS–(BUSINESS WIRE)–At this year’s AAO Event in New Orleans, healthcare technology leader ModMed is demonstrating the latest innovations from its award winning and widely used ModMed® Ophthalmology software suite that is designed to support p…
New Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics announces findings of a real-world adherence analysis of TEPEZZA (teprotumumab-trbw) for the treatment of TED at AAO 2021.
Gemini Therapeutics Announces Poster Presentation at AAO 2021
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced that Raj Maturi, M…
MingSight Completes a New Round of Financing to Accelerate Clinical Development in Chronic Lymphocytic Leukemia and Diabetic Macular Edema
SAN DIEGO–(BUSINESS WIRE)–MingSight Pharmaceuticals announced today the close of a pre-Series B round of $20M, led by Kaitai Capital. The proceeds will be used for the clinical development of MS-553, a new generation inhibitor of protein kinase C (PK…